title: Determinants of the cost-effectiveness of statins.
abstract: OBJECTIVE
  To examine the cost-effectiveness of statins in relation to different measures of effectiveness, differences in efficacy among individual statins, and the risk of coronary heart disease. Efficacy is defined here as the magnitude of the effect produced by a given amount of drug, as demonstrated in placebocontrol trials; i.e., the effectiveness per unit dose.
  
  
  RESULTS
  Treatment guidelines categorize patients by their risk of coronary events and set lower target cholesterol levels for patients at higher risk. Statins vary in their efficacy. If effectiveness is expressed as percent lowering in low-density lipoprotein cholesterol (LDL-C) and relatively little cholesterol lowering is required.as in low-risk patients.even statins of low efficacy provide adequate cholesterol lowering, and drug price is the determining factor of costeffectiveness. For patients at high risk.the primary target group, which has been expanded in recent guidelines.high-efficacy statins are required to meet the more aggressive cholesterol goals, and efficacy is the important determinant of cost-effectiveness. When effectiveness is expressed in terms of life-years saved, the cost-effectiveness of statins as a class for treatment of high-risk patients compares favorably with the cost-effectiveness of generally accepted medical treatments.
  
  
  CONCLUSIONS
  In order to optimize cost-effectiveness, the level of effectiveness required to treat the specific patient or patient group must be considered. Statin efficacy is the major determinant of cost-effectiveness when greater cholesterol lowering is required, i.e., for high-risk patients, who make up the primary target group. Statin price is the more important factor if only limited cholesterol lowering (e.g., 35% or less reduction in LDL) is required.
authors.affiliation: SCRIBCO, Blue Bell, PA 19422, USA. scribbler@verizon.net
authors.forename: Alan
authors.initials: A
authors.lastname: Morrison
authors.forename: Helene
authors.initials: H
authors.lastname: Glassberg
mesh_terms: D008078:Cholesterol, LDL / Q000097:blood; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000191:economics* / Q000401:mortality; D008297:Male; D008329:Managed Care Programs / Q000191:economics; D012307:Risk Factors
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors